FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2529888904> ?p ?o ?g. }

• W2529888904 abstract "Abstract Abstract 4406 We have found only one study aimed to find prognostic significance of abdominal lymph nodes in CLL (E. Montserrat et al, 2007). It was shown that Rai O CLL patients with enlarged abdominal lymph nodes had inferior survival. It merely means that CT scan could early reveal patients with enlarged lymph nodes. This cohort of patients is included in stage 0 only due to the fact of unavailability of CT scan at the times Rai and Binet staging were described (1975, 1977). The aim of the study was to evaluate prognostic significance of abdominal lymph nodes enlargement for the response to FC and FCR Patients and methods 71 untreated CLL patients were included according to the intent to treatment by fludarabine containing regimens (FC and FCR). Staging was performed according to Binet system. Stage B and C patients were included. Lymph nodes were revealed by CT and ultrasound before therapy (Lymph nodes more than 10mm in diameter were considered as abnormal and more than 100 mm in diameter were considered as bulky). CD38 was performed by CytoFlow (cut off 30%). Mutation analysis was done with PCR and sequencing (E.Nikitin, Hematological centre, Moscow), (cut off 98%). CR was defined according to NCI criteria. The patients were treated and followed-up by the single team of physicians, there were no losses of follow-us. SPSS - 17 statistical program was used for analysis. Results Overall response (OR) was 86% (61 pts), the rate of CR was 55% (39 pts), the rate of PR 31% (22 pts). In the whole group, FC: OR 81%, CR 46%, PR 35%. FCR: OR 91%, CR 67%, PR 24%), median of PFS was 26 mons (21 mons for FC and 35 for FCR, p=0.006). CD38 positivity, unmutated type and stage C had adverse prognostic significance in the whole group (p= 0,04; p=0,05; p=0,02), in FCR subgroups, mutation status and CD38 had marginal significance in FCR(p=0.9, p=0.75). Abdominal lymph nodes were enlarged in 41 pts (58%), 16 pts had bulky EAL(23%). PFS was lower in the group of patients with EAL in comparison to patients without EAL(18 and 48 mons, p 0.001). Difference in PFS has been also revealed in FC and FCR subgroups: 16 and 25 mons, p=0,003 for FC; 22 and 56 mons, p=0,01 for FCR (Fig.1) All fludarabine containing regimens resistant patients appeared to have EAL (10 pts). The duration of CR and PR were longer in patients without EAL(resp.p = 0.03 and 0.06, Fig. 2). The differences of PFS were also studied inside the groups defined by standard prognostic markers. CD38-, EAL+ patients had median PFS of 23mons, CD38-, EAL- patients-median not achieved (p= 0.01) CD 38+EAL+patients had median PFS of 12 mons, CD38+EAL- patients – 30 mons (p=0,04) Thus, CD38+ patients without EAL had even better PFS than CD38- patients with EAL. VH-mut+ EAL+ patients had median PFS of 18 mons, VH-mut+ EAL- patients – 58 mons (p=0,06) VH-mut- EAL+ patients had median PFS of 11 mons, VH-mut- EAL- patients – 18 mons (p=0,06) Thus, unmutated patients wit EAL had similar PFS with mutated patients without EAL. Stage B EAL+ patients had median PFS of 20 mons, Stage B EAL- patients – 58 mons (p=0,004) Stage C EAL+ patients had median PFS of 15 mons, Stage C EAL- patients – 21 mons (p=0,05) Thus, patients with stage B without EAL had PFS four times better, than patients with stage C, EAL+. Median PFS is similar in patients stage B EAL+ and stage C EAL-. The response equal to PR and more than PR after three cycles of chemotherapy was more frequent in patients without EAL (65% vs 18%, p < 0,001) Conclusion Enlarged abdominal lymph nodes(EAL) is an adverse prognostic marker for response both to FC and FCR. Differences in PFS according to EAL were also revealed inside standard prognostics subgroups (mutation status and CD38,stage). Even more, PFS of patients with standard adverse prognostic factors without EAL were similar to patients without standard adverse prognostic with EAL. CLL with EAL is a separate entity of CLL. Disclosures: No relevant conflicts of interest to declare." @default.
• W2529888904 created "2016-10-21" @default.
• W2529888904 creator A5024887955 @default.
• W2529888904 creator A5028500521 @default.
• W2529888904 creator A5049857886 @default.
• W2529888904 creator A5057590254 @default.
• W2529888904 creator A5059723473 @default.
• W2529888904 creator A5082220815 @default.
• W2529888904 date "2009-11-20" @default.
• W2529888904 modified "2023-09-29" @default.
• W2529888904 title "CLL with enlarged Abdominal Lymph Nodes (EAL) Is An Entity with Decreased Response to Fludarabine Containing Regimens." @default.
• W2529888904 doi "https://doi.org/10.1182/blood.v114.22.4406.4406" @default.
• W2529888904 hasPublicationYear "2009" @default.
• W2529888904 type Work @default.
• W2529888904 sameAs 2529888904 @default.
• W2529888904 citedByCount "0" @default.
• W2529888904 crossrefType "journal-article" @default.
• W2529888904 hasAuthorship W2529888904A5024887955 @default.
• W2529888904 hasAuthorship W2529888904A5028500521 @default.
• W2529888904 hasAuthorship W2529888904A5049857886 @default.
• W2529888904 hasAuthorship W2529888904A5057590254 @default.
• W2529888904 hasAuthorship W2529888904A5059723473 @default.
• W2529888904 hasAuthorship W2529888904A5082220815 @default.
• W2529888904 hasConcept C126322002 @default.
• W2529888904 hasConcept C126838900 @default.
• W2529888904 hasConcept C141071460 @default.
• W2529888904 hasConcept C142724271 @default.
• W2529888904 hasConcept C146357865 @default.
• W2529888904 hasConcept C151730666 @default.
• W2529888904 hasConcept C2776694085 @default.
• W2529888904 hasConcept C2776755627 @default.
• W2529888904 hasConcept C2779263901 @default.
• W2529888904 hasConcept C2779720271 @default.
• W2529888904 hasConcept C65409693 @default.
• W2529888904 hasConcept C71924100 @default.
• W2529888904 hasConcept C86803240 @default.
• W2529888904 hasConceptScore W2529888904C126322002 @default.
• W2529888904 hasConceptScore W2529888904C126838900 @default.
• W2529888904 hasConceptScore W2529888904C141071460 @default.
• W2529888904 hasConceptScore W2529888904C142724271 @default.
• W2529888904 hasConceptScore W2529888904C146357865 @default.
• W2529888904 hasConceptScore W2529888904C151730666 @default.
• W2529888904 hasConceptScore W2529888904C2776694085 @default.
• W2529888904 hasConceptScore W2529888904C2776755627 @default.
• W2529888904 hasConceptScore W2529888904C2779263901 @default.
• W2529888904 hasConceptScore W2529888904C2779720271 @default.
• W2529888904 hasConceptScore W2529888904C65409693 @default.
• W2529888904 hasConceptScore W2529888904C71924100 @default.
• W2529888904 hasConceptScore W2529888904C86803240 @default.
• W2529888904 hasLocation W25298889041 @default.
• W2529888904 hasOpenAccess W2529888904 @default.
• W2529888904 hasPrimaryLocation W25298889041 @default.
• W2529888904 hasRelatedWork W1986802067 @default.
• W2529888904 hasRelatedWork W2246946424 @default.
• W2529888904 hasRelatedWork W2338351021 @default.
• W2529888904 hasRelatedWork W2511310313 @default.
• W2529888904 hasRelatedWork W2516665755 @default.
• W2529888904 hasRelatedWork W2539288552 @default.
• W2529888904 hasRelatedWork W2549388071 @default.
• W2529888904 hasRelatedWork W2553780248 @default.
• W2529888904 hasRelatedWork W2556453873 @default.
• W2529888904 hasRelatedWork W2559438779 @default.
• W2529888904 hasRelatedWork W2575447455 @default.
• W2529888904 hasRelatedWork W2584187942 @default.
• W2529888904 hasRelatedWork W2588339660 @default.
• W2529888904 hasRelatedWork W2589425291 @default.
• W2529888904 hasRelatedWork W2596208424 @default.
• W2529888904 hasRelatedWork W2620328644 @default.
• W2529888904 hasRelatedWork W2979804808 @default.
• W2529888904 hasRelatedWork W2991660930 @default.
• W2529888904 hasRelatedWork W3096248233 @default.
• W2529888904 hasRelatedWork W3096701704 @default.
• W2529888904 isParatext "false" @default.
• W2529888904 isRetracted "false" @default.
• W2529888904 magId "2529888904" @default.
• W2529888904 workType "article" @default.